Welcome to our dedicated page for NK news (Ticker: NK), a resource for investors and traders seeking the latest updates and insights on NK stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect NK's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of NK's position in the market.
ImmunityBio and NantKwest have finalized a 100% stock-for-stock merger, effective March 10, 2021. The merger was approved by a majority of NantKwest's shareholders at a Special Meeting on March 8, 2021. The combined entity will operate as ImmunityBio, trading under the new ticker IBRX. This merger aims to enhance the development of innovative therapies for cancer and infectious diseases, including a novel COVID-19 vaccine. ImmunityBio boasts over 40 clinical trials and a comprehensive immunotherapy pipeline.
NantKwest, Inc. (NASDAQ: NK) announced that stockholders approved all proposals for the merger with ImmunityBio, Inc. during a special meeting. This merger is set to close on March 9, 2021, pending customary conditions. After the merger, the combined entity will operate under the ImmunityBio name, with shares trading as "IBRX" starting March 10, 2021. NantKwest specializes in natural killer cell-based therapeutics aimed at treating cancer and infectious diseases, further developing its innovative clinical-stage immunotherapy solutions.
ImmunityBio and NantKwest (NASDAQ: NK) have commenced their COVID-19 vaccine trials in South Africa and the U.S., administering the hAd5 vaccine candidate designed to target both spike and nucleocapsid proteins of SARS-CoV-2. Initial doses have been given to nine participants in South Africa and six in each of the two U.S. trials, with a total of 140 participants set to be enrolled. This vaccine aims to elicit a stronger immune response against virus mutations. The companies are also combining operations in a stock-for-stock transaction, expected to close in the first half of 2021.
ImmunityBio announces the appointment of John Brennan, former CIA Director, and Wesley Clark, retired U.S. Army General, to its board of directors. This expansion brings the board to four members, including Chairman Patrick Soon-Shiong and Christobel Selecky. The changes come as the company progresses toward its merger with NantKwest (NK), expected to close in the first half of 2021. Brennan and Clark's experience is anticipated to strengthen the board's oversight capabilities, aligning with ImmunityBio's strategic goals in oncology and infectious diseases.
ImmunityBio announced promising results from its Phase II/III clinical trial for the IL-15RαFc superagonist N-803 combined with BCG in treating BCG-unresponsive non-muscle invasive bladder cancer. Out of 72 evaluable patients, 71% achieved a complete response. The median duration of complete response was 19.2 months, with a 59% probability of maintaining it for at least 12 months. The combination indicates a potential alternative to existing therapies with minimal adverse events reported. Additionally, ImmunityBio is merging with NantKwest (NASDAQ: NK) to enhance oncology and infectious disease treatments.
NantKwest (NASDAQ: NK) and ImmunityBio have received FDA approval to expand Phase I trials for their bivalent COVID-19 vaccine, which targets both the spike and nucleocapsid proteins of SARS-CoV-2. This expansion includes the addition of sublingual and oral boosters, enrolling 105 more participants. Initial non-human primate studies showed promising immune responses. The studies aim to refine dosing and administration methods, potentially enhancing immunity and easing distribution challenges with room-temperature stable formulations.
ImmunityBio presents promising data from its Phase 2b study, QUILT-3.055, focusing on non-small cell lung cancer (NSCLC) at the IASLC's 2020 World Conference. The study evaluated the efficacy of Anktiva (IL-15 superagonist) combined with checkpoint inhibitors in patients who previously progressed on such therapies. Key results showed clinical benefits in 78 patients, with a notable 12% experiencing severe adverse events. The combination therapy demonstrated potential to reinvigorate responses in typically resistant patient groups, accentuating its role in advancing immunotherapy.
NantKwest and ImmunityBio announced early interim results from their PD-L1 t-haNK trials for advanced metastatic pancreatic cancer. The trials revealed that median survival rates more than doubled compared to historical controls, with complete remission observed in patients receiving the PD-L1 t-haNK therapy. A Phase 2 study (QUILT 88) has been initiated to further explore treatment efficacy. This study aims to evaluate survival rates in patients with limited treatment options for pancreatic cancer, a leading cause of cancer deaths in the U.S.
NantKwest (NASDAQ: NK) announced that Dr. Patrick Soon-Shiong will present at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021, at 5:20 a.m. PT. He will discuss a proposed stock-for-stock transaction with ImmunityBio, expected to close in the first half of 2021, creating a major player in immunotherapy focused on oncology and infectious diseases. Dr. Soon-Shiong will also provide updates on clinical progress from both companies. A live webcast will be available on NantKwest's and ImmunityBio's websites.
ImmunityBio announced positive results from the Phase 2/3 trial (QUILT 3.032) for non-muscle invasive bladder cancer, showing a 72% complete response rate in 71 patients receiving Anktiva plus BCG. With a median duration of response at 19.2 months and a 1% rate of serious adverse events, the findings support Anktiva's potential as a treatment alternative for patients with BCG-unresponsive disease. The company plans to file a Biologics License Application following further discussions with the FDA.
